SkQ1

SkQ1, chemically plastoquinonyl decyltriphenylphosphonium, is a member of a family of so-called SkQ compounds that pair the antioxidant plastoquinone with a lipophilic triphenylphosphonium cation ^[1]. The positively charged cation, sometimes called a Skulachev ion, is drawn into mitochondria because these organelles carry a strong negative charge relative to the rest of the cell, so the antioxidant is concentrated precisely where much of the cell's reactive oxygen species is generated ^[1]. The compound was developed by a group at Lomonosov Moscow State University led by the bioenergeticist Vladimir Skulachev ^[1].

The rationale for SkQ1 grows out of the idea that mitochondrial reactive oxygen species contribute to aging and to a range of age-related pathologies, and that concentrating an antioxidant in mitochondria could counter this more effectively than untargeted antioxidants ^[1]. In laboratory studies SkQ1 lowers mitochondrial oxidant levels and has been reported to extend lifespan and delay signs of aging in organisms ranging from fungi and invertebrates to fish and mice ^[3]. In a mouse model of accelerated aging driven by mitochondrial DNA mutations, treatment delayed features such as hair loss, weight loss, and organ damage and modestly lengthened survival ^[3].

The most developed practical use of SkQ1 is in ophthalmology; a very dilute solution is formulated as eye drops, marketed as Visomitin, for dry eye syndrome ^[1]. A multicenter, randomized, double-masked, placebo-controlled trial found that these drops improved measures of tear film stability and reduced corneal damage and dry eye symptoms compared with placebo ^[2]. On the basis of such work the drops were registered in Russia, which led the developers to describe SkQ1 as the first mitochondria-targeted compound to enter medical practice ^[1].

Beyond the approved eye drops in Russia, SkQ1 remains largely an investigational compound, with much of the evidence for its broader effects coming from animal and cell studies rather than large human trials ^[3]. It is not an approved systemic medicine in most countries, and its long-term effects in people are not well characterized outside the ophthalmic setting ^[1].

SkQ1 is best documented as a topical ophthalmic agent (Visomitin eye drops), where controlled trials in dry eye disease found it generally well tolerated, with the most common complaints being transient eye irritation, burning, or stinging on instillation. It is approved as a drug only in Russia and is otherwise treated as a research-grade material; oral and systemic human safety data are very limited, and mitochondria-targeted antioxidants can in principle shift cellular redox balance or act as pro-oxidants at higher concentrations. It should not replace proven medical care, interactions with other drugs are essentially uncharacterized, and consumer-grade powders lack pharmaceutical quality control, so any systemic use should be regarded as experimental and undertaken only with medical guidance.

SkQ1 (10-(6'-plastoquinonyl)decyltriphenylphosphonium) is a mitochondria-targeted antioxidant designed by the Russian bioenergetics researcher Vladimir Skulachev and colleagues at Moscow State University. Building on the Skulachev ion concept, they conjugated the plant antioxidant plastoquinone to a lipophilic triphenylphosphonium cation so that the molecule accumulates selectively within mitochondria, driven by the mitochondrial membrane potential. The approach was formalized in the 2000s, and an eye-drop formulation, Visomitin (Vizomitin), became the first registered drug of this class, approved in Russia in 2012 for dry eye disease.

SkQ1 is well regarded within the mitochondrial-medicine and longevity research fields as a leading example of targeted antioxidant delivery, supported by a substantial body of preclinical work and by clinical registration of its ophthalmic formulation in Russia. Outside that context its reputation is more speculative; claims of systemic anti-aging benefit rest largely on animal studies, Western regulatory approval is absent, and human evidence beyond the eye-drop indication is thin, so enthusiasm is tempered by the gap between mechanism and proven systemic outcomes.